Compare KNSA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNSA | KYMR |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 9.0B |
| IPO Year | 2018 | 2020 |
| Metric | KNSA | KYMR |
|---|---|---|
| Price | $95.50 | $121.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 24 |
| Target Price | $111.57 | ★ $145.22 |
| AVG Volume (30 Days) | 869.4K | ★ 912.7K |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $677,564,000.00 | $39,211,000.00 |
| Revenue This Year | $54.80 | $153.48 |
| Revenue Next Year | $28.50 | N/A |
| P/E Ratio | $83.44 | ★ N/A |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $37.02 | $63.69 |
| 52 Week High | $99.31 | $142.92 |
| Indicator | KNSA | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 47.18 |
| Support Level | $72.76 | $104.96 |
| Resistance Level | $98.90 | $128.95 |
| Average True Range (ATR) | 4.32 | 7.47 |
| MACD | -0.24 | -1.35 |
| Stochastic Oscillator | 68.28 | 14.51 |
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.